Program
Panitumumab
Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.
Drug pagePanitumumab: every studyAll 196 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 351 open or running | phase 3since Jun 10, 2005 | Apr 25, 2002 | Sep 25, 2028phase 3 · NCT06252649 |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 4since Nov 24, 2014 | Nov 24, 2014 | none ahead |
| R-Pharmits history only | 11 open or running | phase 1since Apr 14, 2026 | Apr 14, 2026 | none ahead |
Also a collaborator on its studies: Takeda and Immunex.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Apr 25, 2002.
- Dec 12, 2006Phase 2 study in Colonic NeoplasmsNCT00411450 · 116 enrolled
- Jan 4, 20073 phase 2 studiesNCT00418938, NCT00425204, NCT00425035
- Mar 8, 20072 phase 2 studiesNCT00446446, NCT00454779
- Jul 12, 20072 phase 2 studiesNCT00500760, NCT00508404
- Oct 18, 2007Phase 2 study in NeoplasmsNCT00547157 · 152 enrolled
- Nov 21, 2007Phase 1 study in Colorectal NeoplasmsNCT00563316 · 28 enrolled · United States, Canada
- Jan 31, 2008Phase 2 study in Pancreatic NeoplasmsNCT00613730 · 3 enrolled
- Apr 10, 2008Phase 1 study in Solid TumorsNCT00658658 · 31 enrolled · United States
- Sep 18, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT00756444 · 67 enrolled
- Nov 6, 2008Phase 2 study in Colonic NeoplasmsNCT00819780 · 285 enrolled · United States, Belgium, Canada and more
- Oct 22, 2009Phase 3 study in Colorectal NeoplasmsNCT01001377 · 1,010 enrolled · United States, Australia, Belgium and more
- Mar 31, 2011Phase 3 study in Colorectal NeoplasmsNCT01412957 · 377 enrolled · Brazil, Canada, Chile and more
- Jan 6, 2022Phase 3 study in Colorectal NeoplasmsNCT05198934 · 160 enrolled · United States, Australia, France and more
- Jan 15, 2024Phase 3 study in Colorectal NeoplasmsNCT06252649 · 450 planned · United States, Argentina, Australia and more
Ahead
- Sep 25, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT06252649
TargetBeta
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 35 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06252649Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Sep 25, 2028 | 450 |
| NCT05198934Colorectal Neoplasms · United States, Australia, France and more | 3 | Completed | Jul 16, 2025 | 160 |
| NCT01412957Colorectal Neoplasms · Brazil, Canada, Chile and more | 3 | Completed | Jun 2014 | 377 |
| NCT01001377Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Feb 5, 2013 | 1,010 |
| NCT00819780Colonic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | May 30, 2012 | 285 |
| NCT00756444Squamous Cell Carcinoma of Head and Neck | 2 | Completed | Mar 30, 2012 | 67 |
| NCT00658658Solid Tumors · United States | 1 | Completed | Mar 2015 | 31 |
| NCT00613730Pancreatic Neoplasms | 2 | Terminated | Apr 2009 | 3 |
| NCT00563316Colorectal Neoplasms · United States, Canada | 1 | Completed | Mar 2009 | 28 |
| NCT00547157Neoplasms | 2 | Completed | Dec 2011 | 152 |
| NCT00508404Colorectal Neoplasms | 2 | Completed | Jun 1, 2009 | 154 |
| NCT00500760Head and Neck Neoplasms | 2 | Completed | Mar 29, 2011 | 153 |
| NCT00454779Neoplasm Metastasis · United States, Austria, Belgium and more | 2 | Completed | Jun 11, 2012 | 113 |
| NCT00446446Neoplasms | 2 | Completed | Dec 15, 2010 | 52 |
| NCT00425204Colorectal Neoplasms | 2 | Completed | Sep 2007 | 31 |
| NCT00425035Kidney Neoplasms | 2 | Completed | 115 | |
| NCT00418938Neoplasms | 2 | Completed | May 10, 2012 | 266 |
| NCT00411450Colonic Neoplasms | 2 | Completed | Jan 2009 | 116 |
| NCT00364013Colorectal Neoplasms | 3 | Completed | Aug 1, 2009 | 1,183 |
| NCT00339183Colorectal Neoplasms | 3 | Completed | Apr 1, 2009 | 1,186 |
| NCT00327119Colorectal Neoplasms | 2 | Completed | 50 | |
| NCT00352950Neoplasms | 1 | Withdrawn | 0 | |
| NCT00115765Colorectal Neoplasms | 3 | Completed | May 31, 2007 | 1,053 |
| NCT00113776Colorectal Neoplasms | 2 | Completed | ||
| NCT00113763Colorectal Neoplasms | 3 | Completed | Oct 1, 2008 | 463 |
| NCT00111774Colorectal Neoplasms | 2 | Completed | 150 | |
| NCT00111761Colorectal Neoplasms | 2 | Completed | Feb 2008 | 43 |
| NCT00101920Carcinoma, Non-Small-Cell Lung | 2 | Completed | Dec 2004 | 50 |
| NCT00101907Lung Neoplasms | 1 | Terminated | Jun 2007 | 41 |
| NCT00094835Lung Neoplasms | 2 | Completed | Mar 2007 | 51 |
| NCT00091806Neoplasms | 1 | Completed | Apr 2006 | 86 |
| NCT00089635Colorectal Neoplasms | 2 | Completed | Jan 1, 2007 | 203 |
| NCT00083616Colorectal Neoplasms | 2 | Completed | May 2007 | 185 |
| NCT00061126Prostatic Neoplasms · United States | 2 | Completed | 50 | |
| NCT00034346Carcinoma, Non-Small-Cell Lung | 2 | Completed | 194 |
How it is read
Names in the registry
- “Panitumumab”, 29 entries
- “ABX-EGF”, 5 entries
- “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
- “Panitumumab (ABX-EGF)”, 2 entries
- “RPH-030”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 25 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colonic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.